Aquestive Q3 net loss $15.4M; Anaphylm PDUFA Jan 31, 2026, launch prep ongoing

Aquestive Therapeutics, Inc.

2025-Q3 EPS reported -$0.51 vs consensus -$0.14 ▼ miss (-277.2%)

Total revenue $12.8M (+4% YoY excluding one-time 2024 deferred revenue); net loss $15.4M ($0.14/sh) vs $11.5M loss in Q3 2024.
Cash $129.1M; full-year 2025 revenue guidance $44-50M, non-GAAP adjusted EBITDA loss $47-51M.
Anaphylm NDA on track for Jan 31, 2026 PDUFA; FDA will not hold AdCom; US launch planned Q1 2026 if approved.
Two new Anaphylm patents issued Oct 2025 extending protection to 2037; IND for AQST-108 topical epinephrine gel for alopecia areata on track for Q4 2025.
Added clinical leadership for AdrenaVerse pipeline; supply chain largely unaffected by tariffs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.